Buscar
RAPT Therapeutics Inc
RAPTAñadir a la lista de seguimiento
58.020USD
0.0000.00%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
1.68BCap. mercado
PérdidaP/E TTM
Más Datos de RAPT Therapeutics Inc Compañía
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
Información de RAPT Therapeutics Inc
Símbolo de cotizaciónRAPT
Nombre de la empresaRAPT Therapeutics Inc
Fecha de salida a bolsaOct 31, 2019
Director ejecutivoWong (Brian)
Número de empleados68
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 31
Dirección561 Eccles Ave
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Teléfono16504899000
Sitio Webhttps://rapt.com/
Símbolo de cotizaciónRAPT
Fecha de salida a bolsaOct 31, 2019
Director ejecutivoWong (Brian)
Ejecutivos de RAPT Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Brian Wong, M.D., Ph.D.
Dr. Brian Wong, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Rodney K. B. Young
Mr. Rodney K. B. Young
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Dirk Brockstedt, Ph.D.
Dr. Dirk Brockstedt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
--
-100.00%
Ms. Linda Kozick
Ms. Linda Kozick
Independent Director
Independent Director
--
-100.00%
Ms. Lori Lyons-Williams
Ms. Lori Lyons-Williams
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Dr. Scott N. Braunstein, M.D.
Dr. Scott N. Braunstein, M.D.
Independent Director
Independent Director
--
--
Dr. Ashley Dombkowski, Ph.D.
Dr. Ashley Dombkowski, Ph.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Brian Wong, M.D., Ph.D.
Dr. Brian Wong, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Rodney K. B. Young
Mr. Rodney K. B. Young
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Dirk Brockstedt, Ph.D.
Dr. Dirk Brockstedt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
--
-100.00%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de RAPT Therapeutics Inc?
Los cinco principales accionistas de RAPT Therapeutics Inc son: Dr. William (Bill) Ho, M.D., Ph.D.
¿Cuántas instituciones poseen acciones de RAPT Therapeutics Inc (RAPT)?
A fecha de 2026Q1, 301 instituciones poseen acciones de RAPT Therapeutics Inc, con un valor de mercado combinado de aproximadamente 29.16M, lo que representa el 100.68% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 8207720.00.